LAG3 and cancer: Examples include ImmTAC® molecules, which are engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively target these cancer cells via an anti-CD3 immune-activating effector function, and could be combined with LAG-3 inhibitors.